Licensing opportunity
Scientists at Cancer Research Technology Ltd’s (CRT) drug discovery laboratories have generated data showing that CRT0066101, a potent and selective inhibitor of protein kinase D, inhibits the growth of pancreatic tumours.
The research, carried out in collaboration between CRT and the University of Texas MD Anderson Cancer Center, shows for the first time that an inhibitor of PKD can slow the growth of tumours in pancreatic cancer models. CRT0066101, an orally administered small molecule, is also effective at inhibiting the growth of tumours in a lung cancer model.
PKD is a relatively newly identified family of serine/threonine kinases discovered by the research charity Cancer Research UK, and found to play a central role in the development of a number of cancers. CRT is the technology transfer arm of the charity.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
